Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

65.98 -0.95 (-1.42%)
Streaming Delayed Price Updated: 12:15 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Acquire MiroBio
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Second Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
From Gilead Sciences, Inc.
Via Business Wire
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Gilead Sciences, Inc.
Via Business Wire
Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?
When you're on the hunt for a great long-term dividend stock, you may want the perfect stock. The Dividend Aristocrats or Dividend Kings may come to mind first — companies that have proven they offer a... 
Via MarketBeat
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
From Gilead Sciences, Inc.
Via Business Wire
Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
Global Liposome Drug Delivery Market Size was estimated at USD 3316.64 million in 2021 and is projected to reach USD 7768.01 million by 2028, exhibiting a CAGR of 12.93% during the forecast period 
Via SBWire
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
From Gilead Sciences, Inc.
Via Business Wire
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
From Gilead Sciences, Inc.
Via Business Wire
Gilead Joining the Global Access to Oncology Medicines Coalition
SOURCE: Gilead Sciences 
Via 3BL Media
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
From Gilead Sciences, Inc.
Via Business Wire
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
From Gilead Sciences, Inc.
Via Business Wire
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
From Gilead Sciences, Inc.
Via Business Wire
Michael Elliott Named to 2022 Empower Advocate Executive Role Model List.
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.